BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China; November 10, 2025: Bio-TheraSolutions (688177:SH; “Bio-Thera”), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and biosimilars, today announcedthat it has entered into an exclusive commercialization and license agreementwith Dr. Reddy’...
GUANGZHOU,China - Bio-Thera Solutions (688177.S H ), a commercial-stage biopharmaceutical companydeveloping innovative therapies and biosimilars, announced that its partner, HikmaPharmaceuticals USA Inc. officially launched STARJEMZA™ (ustekinumab-hmny)Injection, a biosimilar referencing STELARA®...
GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and biosimilars, todayannounced an expansion of its partnership with Intas Pharmaceuticals for BAT2506, aproposed golimumab biosimilar, through an exclusive...